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 Introduction 
 When a compound is prescribed, the aim is to attain 
targeted effects (e.g. bactericidal, analgesic or normaliza-
tion of blood pressure), preferably without disproportional 
side effects (e.g. drug toxicity, hypotension or tachycardia). 
Clinical pharmacology aims to estimate such side effects at 
the level of the population or, preferably, the individual  [1, 
2] . Pharmacokinetics (PK) describes the relationship be-
tween a concentration in a specific compartment (e.g. plas-
ma, cerebrospinal fluid and bronchial epithelial lining flu-
id) and time (concentration/time, ‘what the body does to 
the drug’). Pharmacodynamics (PD) describes the relation-
ship between a concentration in a specific compartment 
and (adverse) effects (concentration/effect, ‘what the drug 
does to the body’). The concepts of clinical pharmacology 
obviously also apply to neonates, but their physiological 
characteristics require a tailored approach  [3, 4] .
 Covariate analysis is an important tool for translating 
information on the newborn population in general to each 
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 Abstract 
 Drug therapy is a powerful tool for improving neonatal out-
come. Despite this, neonatologists still routinely prescribe 
off-label compounds developed for adults and extrapolate 
doses from those used for children or adults. Knowledge in-
tegration through pharmacokinetic modeling is a method 
that could improve the current situation. Such predictive 
models may convert neonatal pharmacotherapy from ex-
plorative to confirmatory. This can be illustrated by research 
projects related to the prediction of neonatal renal clearance 
and neonatal glucuronidation. This type of model will also 
improve the current knowledge of neonatal (patho)physiol-
ogy. In the meanwhile, the fields of clinical pharmacology 
(e.g. pharmacokinetic/pharmacodynamic modeling and 
pharmacogenetics) and neonatology (e.g. whole-body cool-
ing and the lower limit of viability) have both matured, re-
sulting in new research topics. However, in order for the 
modeling and the newly emerging topics to become effec-
tive tools, they need to be tailored to the specific character-
istics of neonates. Consequently, the field of neonatal phar-
macotherapy needs dedicated neonatologists who continue 
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neonate in need of individualized pharmacotherapy  [3, 4] . 
Covariates are specific characteristics that explain in part 
the inter- and intra-individual PK/PD variability. The 
most obvious covariates in neonates relate to growth and 
development, reflected and quantified by birth weight, 
current weight or age, i.e. postnatal, gestational or post-
menstrual age. There is already at least one order of vari-
ability in weight (<0.5 up to 5 kg) while both the height 
velocity rate (10–20 cm/year) and the increase in body 
weight (50% increase in the first 6 weeks) reflect the dy-
namics of a rapidly evolving biological system in perinatal 
life. The maturation-related variability is further aggra-
vated by interfering disease characteristics (e.g. renal fail-
ure, sepsis and growth restriction) or treatment modalities 
(e.g. co-medication, extracorporeal membrane oxygen-
ation and whole-body cooling). Moreover, maturation 
(e.g. receptor expression, receptor activity, cellular metab-
olism and enzyme activity) interrelates with growth. Some 
tissues may be more sensitive to specific compounds in 
early life, irrespective of a given concentration or expo-
sure, whereas others will be less sensitive. This will affect 
population-specific PD. Beyond clinical pharmacology, 
the most crucial characteristic of perinatology is, in fact 
that despite the limited size, there is extensive variability, 
related to rapidly evolving physiology  [3, 4] .
 Drug therapy is a powerful tool for improving neonatal 
outcome. Despite this, neonatologists still routinely pre-
scribe off-label compounds and extrapolate doses and in-
dications from those used for children or adults, without 
fully considering perinatal physiology. PK/PD modeling 
is an emerging tool that can improve the current situation 
by its capacity to convert neonatal pharmacotherapy from 
explorative to confirmatory. This can be illustrated by 
modeling projects on neonatal renal clearance and neona-
tal glucuronidation. Such models also improve the knowl-
edge of neonatal (patho)physiology. This is illustrated by 
recent data on maturational differences in renal versus he-
patic elimination routes and drug-drug interactions. Fi-
nally, both clinical pharmacology [e.g. PK/PD modeling 
and pharmacogenetics (PG)] and neonatology (whole-
body cooling and the lower limit of viability) have ma-
tured, resulting in new topics for research.
 Modeling as a Structured Approach to Improve 
Knowledge of Pharmacotherapy 
 A powerful tool to improve neonatal pharmacother-
apy and facilitate clinical studies is knowledge integra-
tion through PK modeling. PK modeling is through 
mechanism-based PK or physiology-based (PB)-PK  [4–
7] . Mechanism-based models apply a bottom-up ‘from 
compound to model’ concept: based on drug-specific 
observations, covariates are described, resulting in 
mechanism-based models. PB-PK applies a top-down 
‘from physiology to clinical observations’ concept: based 
on available data on neonatal physiology (e.g. weight, 
cardiac output and renal function), a PB-PK model can 
be developed  [4–7] . These models hold promise for pre-
dicting the PK/PD of compounds if the normal clear-
ance routes are known. Such approaches were recently 
reported for drug-related clearance through either glo-
merular filtration rate  [8, 9] or glucuronidation in early 
life  [10] .
 For the renal model, a covariate model characterizing 
developmental changes in the clearance of amikacin in 
neonates was developed based on birth weight, postnatal 
age and ibuprofen exposure  [8] . Assuming that such a 
model contains physiological information on glomerular 
filtration rate ontogeny, the amikacin covariate model 
was subsequently applied to datasets of other aminogly-
cosides and glycopeptides (i.e. netilmicin, gentamicin, to-
bramycin and vancomycin). It was hereby documented 
that the descriptive and predictive properties of the mod-
els developed using the amikacin covariate model were 
good, and were fairly similar to the independent reference 
models, with similar clearance values being obtained with 
both approaches  [9] . This study hereby confirmed that 
neonatal covariate models may contain physiological in-
formation since information derived from one drug can 
be used to describe other drugs. This approach may be 
used to optimize sparse data analysis and to derive indi-
vidualized dosing algorithms for drugs in newborns. Such 
dosing algorithms obviously need prospective validation, 
since Zhao et al.  [11] illustrated the potential hazards re-
lated to the transfer of published vancomycin models to 
different clinical settings. The predictive performance of 
6 earlier published models was evaluated and differences 
were found in the predictive performance of models for 
vancomycin PK in neonates. This means, in essence, that 
a model described in a cohort in a given hospital does not 
automatically predict data for another cohort in another 
hospital. In this specific example, it was concluded that 
dosage individualization of vancomycin in neonates 
should consider not only clinical characteristics but also 
the methods used to measure serum creatinine and van-
comycin  [11] . A similar effort has been reported for glu-
curonidation, based on morphine glucuronidation in
neonates, subsequently extrapolated to zidovudine glu-
curonidation  [10] .
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 Developmental Pharmacology Reflects 
Developmental Physiology 
 The different routes of elimination do not mature si-
multaneously but all have their process-specific matura-
tional pattern (e.g. glomerular filtration vs. renal tubular 
excretion, CYP2D6 vs. CYP3A4/5 or renal vs. hepatic 
clearance)  [1–4] . This implies that it is important to inte-
grate the ontogeny-related knowledge of the different 
elimination pathways to be able to predict compound-
specific, phenotypic in vivo observations in neonates. 
There is no such thing as a neonatal kidney or liver, but 
only newborns in need of improved pharmacotherapy. 
This also means that specific settings (renal failure, he-
patic failure or drug-drug interactions) described in chil-
dren or adults need to be interpreted cautiously in the 
newborn by taking the available knowledge on develop-
mental physiology into account.
 Metabolites like O-desmethyl tramadol (analgesia), 
morphine glucuronides (analgosedation) or 1-hydroxy-
midazolam (sedation) may accumulate in neonates not 
because the metabolic clearance is already very effective, 
but because the subsequent renal elimination of the me-
tabolites is even less effective  [12] . The same holds true 
for propylene glycol, an alcohol commonly used as an ex-
cipient in drug formulations. In adults, primary renal 
elimination accounts for 45% and hepatic metabolic 
clearance through alcohol dehydrogenase for 55%. In ne-
onates, the contribution of primary renal elimination was 
much more limited (15–25%) while the major route for 
clearance was through hepatic metabolism  [13] . The phe-
notypic result is that propylene glycol clearance in neo-
nates is low and depends strongly on the hepatic meta-
bolic capacity. This likely explains the side effects de-
scribed with Kaletra syrup [1 ml contains 80 mg of 
lopinavir co-formulated with 20 mg of ritonavir + excip-
ients, including 356.3 mg of ethanol (42.4% v/v) and 152.7 
mg of propylene glycol (15.3% w/v)] administration in 
neonates. This formulation contains propylene glycol 
and ethanol and simultaneous exposure results in accu-
mulation through competition for hepatic clearance. In 
contrast, the associated renal failure, commonly de-
scribed as a risk factor for propylene glycol accumulation 
in adults, is likely of limited relevance in neonates  [13] .
 Similar to excipient-excipient interactions, drug-drug 
interactions are only anecdotally explored in neonates. 
Salem et al.  [14]  recently reported a ‘PBPK-model’ to pre-
dict drug-drug interactions throughout pediatric life. For 
a theoretical compound metabolized 50% by CYP2D6 
and CYP3A4 pathways at birth, co-administration of ke-
toconazole (3 mg/kg, CYP3A4 inhibitor) resulted in a 
1.65-fold difference between inhibited versus uninhibited 
concentration time profiles compared to 2.4-fold in 
1-year-olds and 3.2-fold in adults. Obviously, neonates 
could be more sensitive to such PD interactions than 
adults.
 Emerging Clinical Research Topics 
 Pharmacogenetics 
 The idea of individualized clinical pharmacology 
through integration of PG reflects the fact that specific 
(side) effects are not merely randomly distributed. PG 
explores interindividual differences in drug response re-
lated to genetic variations, i.e. polymorphisms. Genetic 
variations can affect drug disposition through modifying 
receptor sensitivity or differences in drug metabolism. 
This obviously holds promise for the tailoring of perina-
tal clinical pharmacology beyond the usual covariates 
like age, weight or disease characteristics  [15] . There are 
illustrations on the integration of PG and age-related 
maturation (i.e. ontogeny) to improve the prediction of 
phenotypic drug metabolism [cytochrome P450 (CYP) 
C219, CYP 2D6 or N-acetyl transferase (NAT) 2]  [16–
18] . Based on in vivo  observations of pantoprazole (CYP 
2C19), tramadol (CYP2D6) and isoniazide metabolic 
clearance, respectively, an age-related impact of specific 
polymorphisms was documented. Obviously, this is lim-
ited to isoenzymes that are sufficiently active already in 
early life. This likely explains the absence of a link be-
tween CYP2C8 and CYP2C9 polymorphisms and the re-
sponse to ibuprofen to induce closure of the patent duc-
tus arteriosus  [19] .
 More importantly, PG studies in perinatal life should 
go beyond confirmation of associations described in 
adults and explore the impact of PG as a covariate limited 
to perinatal life during which the genotype-phenotype 
concordance still exists  [15, 16] . This includes issues like 
fetal malformations, breastfeeding or neonatal clinical 
syndromes. A recent illustration of such an approach is 
the impact of polymorphisms on the severity of neonatal 
abstinence syndrome following maternal opioid intake 
 [20] . While the median length of stay for term neonates 
was 35 days, specific catechol-O-methyltransferase 
(COMT, 158A>G) and μ-opioid receptor (OPRM1, 
118A>G) polymorphisms were associated with a median 
reduction of 10.8 and 8.5 days, respectively. Interestingly, 
breastfeeding itself (on univariate analysis) resulted in a 
reduction of 18 days  [20] .
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 This confirms findings reported by Sistonen et al.  [21] 
on the links between genetic polymorphisms in mothers 
and their infants and the variation in response to stan-
dard doses of maternal opioids (e.g. codeine). The au-
thors hereby explored the associations between poly-
morphisms in CYP2D6, UDP-glucuronosyltransferase 
2B7 (UGT2B7), P-glycoprotein (ABCB1), OPRM1, 
COMT genes and central nervous depression in 111 in-
fants during breast-feeding. A model combining specific 
maternal-risk genotypic polymorphisms (CYP2D6 and 
ABCB1) was associated with central nervous depression 
in both the mothers (OR 2.74) and their offspring (OR 
2.68)  [21] .
 Thermopharmacology in Neonates 
 Therapeutic hypothermia is an effective and valid 
treatment in term newborns following perinatal asphyx-
ia. This relates to the effect of hypothermia on cerebral 
metabolism, but hypothermia itself also affects physio-
logical functions such as circulation and metabolic activ-
ity  [22] . Consequently, this modality may affect physico-
chemical properties and the PK/PD of the drugs. These 
aspects are covered by thermopharmacology, a term re-
cently introduced into neonatal pharmacology by Van 
den Broek et al.  [23, 24] . However, in current practice, 
hypothermia is an additional intervention in neonates 
with peripartal asphyxia. Based on currently available in 
vivo  observations, it seems that primary renal elimina-
tion of aminoglycosides, for example, is not further re-
duced when hypothermia is applied and that asphyxia 
itself already reduces clearance  [25] . In contrast, meta-
bolic clearance seems to be reduced as illustrated for li-
docaine (dependent on hepatic blood flow), morphine 
(glucuronidation) or phenobarbital (dependent on he-
patic drug metabolism)  [23, 24] . Besides PK effects, there 
are also some PD-related effects since the transition rate 
from a continuous normal voltage to a discontinuous 
normal voltage aEEG background level seems to be re-
duced in hypothermic asphyxiated newborns in compar-
ison to in a normothermic setting. Similarly, the growth 
of bacteria also depends on temperature, and hypother-
mia may affect the PK/PD relation of antibiotics in neo-
nates.
 Clinical Pharmacology at the Limit of Viability 
 The overall outcome – including both mortality and 
(co)morbidity – in extreme preterm neonates strongly 
depends on their age at birth, weight at birth and gender. 
Despite this, the pharmacological tools commonly used 
at the limit of viability when compared to less-immature 
neonates are not fundamentally different, the dosing is 
commonly extrapolated from the neonatal practices for 
less-immature neonates, and none of these practices takes 
gender-specific modalities into account. Perhaps we 
should consider additional subpopulations within neona-
tal intensive care. The post hoc analysis on the age-depen-
dent magnitude and direction of neurodevelopmental 
outcome following prophylactic thyroid hormone sup-
plementation may serve as an illustration here  [26] . A 
gestational age-dependent effect of thyroxine on neuro-
developmental outcome was found in post hoc subgroup 
analyses up until the age of 10 years. Thyroxine treatment 
was associated with improved mental, motor and neuro-
logical outcomes in infants <28 weeks’ gestation, but with 
worse mental and neurological outcomes in infants of 
 ≥ 29 weeks’ gestation  [26] .
 Drug therapy is a powerful tool for improving neona-
tal outcome, but may also result in side effects. Adverse 
drug reactions in critically ill newborns may cause harm 
that further increases morbidity or mortality. However, 
differentiation of adverse drug reactions from reactions 
related to immaturity or disease (e.g. renal or hepatic dys-
function) is difficult, while we take it for granted that the 
overall rate of (co)morbidity in extremely preterm neo-
nates at the limit of viability is high  [27] . Similar to PG, 
pharmacovigilance also needs to be tailored to the spe-
cific characteristics of newborns. The decades that were 
needed to document appropriate oxygen targets for pre-
term infants, or more recently, the dexamethasone obser-
vations or the trends towards less-invasive ventilation 
strategies should at least raise awareness that any treat-
ment intended to improve outcome in neonates may, in 
itself, have unanticipated (long-term outcome) side ef-
fects  [28–30] . In a recent systematic review on perinatal 
interventions, Teune et al.  [31]  documented that unfor-
tunately only 40/249 (16%) randomized controlled trials 
followed neonates after discharge from the hospital, with-
out any improvement in consecutive time intervals (15% 
before 1990, 15% between 1990 and 2000 and 19% since 
2001).
 Concluding Remarks 
 Effective pharmacotherapy depends on predictable PK 
and PD. In both these aspects, newborns can differ sig-
nificantly from children or adults. Extrapolation of safety 
and efficacy can be made more reliable when methods 
developed in other fields of clinical pharmacology can be 
integrated into neonatal clinical research and care. These 
D
ow
nl
oa
de
d 
by
: 
Er
as
m
us
 U
ni
v.
of
 R
ot
te
rd
am
 M
ed
ica
l L
ib
ra
ry
   
   
   
   
  
14
9.
12
6.
75
.1
 - 
3/
23
/2
01
6 
8:
56
:3
8 
AM
 Allegaert  /van den Anker  
 
Neonatology 2014;105:344–349
DOI: 10.1159/000360648
348
methods include modeling, PG and pharmacovigilance, 
but they will need to be tailored to the needs and charac-
teristics of neonates to turn them into effective tools. 
Consequently, the field of neonatal pharmacotherapy 
needs dedicated neonatologists who continue to raise the 
awareness that off-label practices, eminence-based dos-
ing regimens and the absence of neonatal drug formula-
tions continue to reflect suboptimal care.
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